Thoratec® Reports First Quarter 2014 Results -Revenue of $125.7 million for the first quarter of 2014 -GAAP net income per diluted share of $0.32, and non-GAAP income per net diluted share of $0.41 -Company reiterates 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis PR Newswire PLEASANTON, Calif., May 6, 2014 PLEASANTON, Calif., May 6, 2014 /PRNewswire/ --Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today reported its financial results for the first quarter of 2014. "Our operational and financial progress in the first quarter provides a solid foundation for a successful 2014," said Gary F. Burbach, President and Chief Executive Officer. "Performance in the quarter was driven by continued growth in HeartMate II, along with exceptional results in our CentriMag acute product line," he added. For the quarter ended March 29, 2014, Thoratec reported revenues of $125.7 million, a seven percent increase versus revenues of $117.7 million in the same period a year ago. Net income on a GAAP basis was $18.2 million, or $0.32 per diluted share, compared to GAAP net income of $18.2 million, or $0.31 per diluted share, in the same period last year. Non-GAAP net income, which is described later in this press release, was $23.7 million, or $0.41 per diluted share in the first quarter of 2014, compared to non-GAAP net income of $24.0 million, or $0.41 per diluted share, in the first quarter of 2013. "We remain excited about upcoming pipeline opportunities with HeartMate III and HeartMate PHP, both of which we anticipate will begin clinical trials in the near future," Burbach commented. "We continue to expect that our attractive end market opportunity combined with technological innovation will drive strong future growth." First Quarter of 2014 Financial Results Thoratec reported revenues of $125.7 million in the first quarter of 2014. The HeartMate product line contributed $110.0 million, an increase of seven percent, driven by expansion of our international business, while the CentriMag product line contributed $13.0 million. GAAP gross margin in the first quarter of 2014 was 68.2 percent compared to 70.2 percent in the same quarter last year. Non-GAAP gross margin, described later in this press release, was 69.5 percent compared to 72.1 percent in the same quarter last year. The decrease in GAAP and non-GAAP gross margin was due primarily to inventory-related charges and manufacturing variances, in part offset by favorable product mix. In addition, GAAP gross margin was positively affected by lower intangible assets amortization expense. GAAP operating expenses in the first quarter of 2014 were $58.8 million compared to $59.3 million in the same quarter last year. Non-GAAP operating expenses, described later in this press release, were $52.3 million compared to $52.8 million in the same quarter last year. The decrease in both GAAP and non-GAAP operating expenses was primarily due to timing of project-related and other administrative expenses offset by higher personnel costs. The company's GAAP effective tax rate in the first quarter of 2014 was 32.6 percent versus 25.9 percent a year ago. The non-GAAP tax rate, which is described later in this press release, was 32.8 percent versus 27.9 percent in the same period last year. The increase in both the GAAP and non-GAAP effective tax rates was primarily due to the lack of federal R&D credits in the absence of enacted legislation. Cash and investments were $299.4 million as of March 29, 2014, compared to $310.0 million as of December 28, 2013. The company repurchased $13.5 million of stock during the first quarter of 2014. GUIDANCE The following statements are based on current expectations. These statements are forward-looking and actual results may differ materially. For a more detailed discussion of forward-looking statements, please see the additional information below. The company reiterates fiscal 2014 guidance for revenues in a range of $520 million to $535 million and net income per diluted share of $1.28 to $1.38 on a GAAP basis and $1.72 to $1.82 on a non-GAAP basis. Gross margin is expected to be approximately 70 percent on a GAAP basis and 71 percent on a non-GAAP basis. We expect the effective tax rate to be approximately 32 percent on both a GAAP and non-GAAP basis. CONFERENCE CALL/WEBCAST INFORMATION Thoratec will hold a conference call to discuss its financial results and operating activities for all interested parties at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (719) 325-4824, passcode 6338556. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available via the Internet at http://www.thoratec.com. A replay of the conference call will be available through Tuesday, May 13, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 6338556. GAAP TO NON-GAAP RECONCILIATION Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by the company's products and certain costs of producing those revenues, such as costs of product sales, research and development and selling, general and administrative expenses. We use the following measures, which are not calculated in accordance with Generally Accepted Accounting Principles ("GAAP"): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP tax rate, non-GAAP net income, and non-GAAP net income per diluted share. These are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. These non-GAAP financial measures are calculated by excluding certain GAAP financial items that we believe have less significance to the day-to-day operation of our business. The company has outlined below the type and scope of these exclusions and the limitations on the use of the non-GAAP financial measures as a result of these exclusions. Management uses these non-GAAP financial measures for financial and operational decision making, including in the determination of employee annual cash incentive compensation, as a means to evaluate period-to-period comparisons, as well as comparisons to our competitors' operating results. Management also uses this information internally for forecasting and budgeting, as it believes that the measures are indicative of Thoratec's core operating results. Management also believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company's business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist in analyzing future trends. Non-GAAP net income consists of GAAP net income, excluding, as applicable, the tax-effected impact of share-based compensation expense, the amortization of purchased intangible assets, and acquisition-related contingent consideration adjustments. Non-GAAP net income per diluted share is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis. Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense and the amortization of purchased intangible assets. Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, the amortization of purchased intangible assets, and acquisition-related contingent consideration adjustments. Non-GAAP tax expense consists of the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income. Management believes that it is useful in measuring Thoratec's operations to exclude the amortization of purchased intangible assets. These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events. Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods. The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec management, which believes that share-based compensation expense is not directly attributable to the underlying performance of the company's business operations. Thoratec management has excluded acquisition-related contingent consideration adjustments from GAAP results to allow investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods. There are a number of limitations related to the use of non-GAAP financial measures. First, non-GAAP financial measures exclude some costs, namely share-based compensation, that are recurring expenses. Second, share-based compensation is part of an employee's compensation package and as such may be useful for investors to consider. Third, the components of costs that we exclude in our non-GAAP financial measures may differ from components that our peer companies exclude when they report their results from operations. Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP. However, these measures may provide additional insight into Thoratec's financial results. Investors and potential investors are strongly encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with their most directly comparable GAAP financial results and not to rely on any single financial measure to evaluate our business. The reconciliations of the forward looking non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables below include all information reasonably available to Thoratec at the date of this press release. These tables include adjustments that we can reasonably predict. Events that could cause the reconciliation to change include acquisitions and divestitures of business, goodwill and other asset impairments and sales of marketable equity securities. The following table includes the GAAP condensed consolidated balance sheets as of March 29, 2014 and December 28, 2013: THORATEC CORPORATION Condensed Consolidated Balance Sheets (unaudited) (in thousands) March 29, 2014 December 28, 2013 ASSETS Current assets: Cash and cash equivalents $ $ 108,653 139,099 Short-term available-for-sale investments 186,535 166,691 Receivables, net of allowances of $2,396 in 77,220 71,418 2014 and $2,163 in 2013 Inventories 59,345 60,293 Deferred tax assets 15,161 15,161 Income tax receivable 9,781 5,733 Prepaid expenses and other assets 8,196 7,272 Total current assets 464,891 465,667 Property, plant and equipment, net 55,084 55,163 Goodwill 207,026 205,764 Purchased intangible assets, net 34,593 36,403 Long-term available-for-sale investments 4,247 4,234 Other long-term assets 23,301 24,476 Total Assets $ $ 789,142 791,707 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ $ 15,923 17,599 Accrued compensation 17,942 22,759 Contingent liabilities, current portion 9,189 6,962 Other accrued liabilities 29,989 27,001 Total current liabilities 73,043 74,321 Long-term deferred tax liability 1,876 2,224 Other long-term liabilities 12,317 12,105 Contingent liabilities, non-current portion 26,728 36,384 Total Liabilities 113,964 125,034 Shareholders' equity: Common shares: no par, authorized 100,000; issued and outstanding 56,885 in 2014 and - - 56,904 in 2013 Additional paid-in-capital 625,085 621,589 Retained earnings 62,548 57,587 Accumulated other comprehensive loss (12,455) (12,503) Total Shareholders' Equity 675,178 666,673 Total Liabilities and Shareholders' Equity $ $ 789,142 791,707 The following table includes the GAAP income statement for the three months ended March 29, 2014 and March 30, 2013: THORATEC CORPORATION Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for per share data) Three Months Ended March 29, 2014 March 30, 2013 Product sales $ 125,697 $ 117,725 Cost of product sales 40,026 35,073 Gross profit 85,671 82,652 Operating expenses: Selling, general and administrative 35,501 34,745 Research and development 23,339 24,513 Total operating expenses 58,840 59,258 Income from operations 26,831 23,394 Other income and (expense): Interest expense (0) (4) Interest income and other 247 1,117 Income before income taxes 27,078 24,507 Income tax expense (8,839) (6,337) Net income $ 18,239 $ 18,170 Net income per share- Basic: $ $ 0.32 0.32 Net income per share- Diluted: $ $ 0.32 0.31 Shares used to compute net income per share: Basic 56,840 57,486 Diluted 57,666 58,507 The following table presents our quarterly revenues by source for the first quarter of 2014 and the full year 2013: THORATEC CORPORATION Quarterly Revenue Analysis (Unaudited) (in millions) Three Months Ended March 29, December 28, September June 29, March 30, 28, 2014 2013 2013 2013 2013 Revenue by Product Line HeartMate $ $ $ $ $ 110.0 113.0 112.8 115.7 102.9 CentriMag (1) 13.0 11.0 10.4 11.5 10.4 PVAD & IVAD 2.3 3.4 2.6 2.7 3.8 Other 0.4 0.8 0.6 0.6 0.6 Total $ $ $ $ $ 125.7 128.2 126.4 130.5 117.7 Revenue by Category Pump $ $ $ $ $ 89.3 90.4 87.1 93.5 84.3 Non-Pump 36.0 37.0 38.7 36.4 32.8 Other 0.4 0.8 0.6 0.6 0.6 Total $ $ $ $ $ 125.7 128.2 126.4 130.5 117.7 Revenue by Geography United States $ $ $ $ $ 95.6 99.8 99.6 98.8 92.3 International 30.1 28.4 26.8 31.7 25.4 Total $ $ $ $ $ 125.7 128.2 126.4 130.5 117.7 (1) CentriMag includes PediMag/PediVAS® sales The following table presents our quarterly HeartMate II pump units by geography for the first quarter of 2014 and the full year 2013: THORATEC CORPORATION Quarterly Heartmate II Pump Units (1) (Unaudited) Three Months Ended Units by Geography March 29, December 28, September 28, June 29, March 2014 2013 2013 2013 30, 2013 United States 701 733 713 748 689 International 263 240 241 277 205 Total 964 973 954 1,025 894 (1) Excludes CentriMag, PediMag/PediVAS and PVAD/IVAD units The following table reconciles the specific items excluded from GAAP net income in the calculation of non-GAAP net income and diluted net income per share for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Net Income (Unaudited) (in thousands, except for per share data) Three Months Ended Net income reconciliation March 29, 2014 March 30, 2013 Net income on a GAAP basis $ $ 18,239 18,170 Share-based compensation expense: - Cost of product sales 621 571 - Selling, general and administrative 4,025 3,683 - Research and development 2,136 1,913 Amortization of purchased intangibles: - Cost of product sales 1,013 1,714 - Selling, general and administrative 760 751 - Research and development 132 82 Acquisition-related contingent consideration adjustments: - Selling, general and administrative 1,088 - - Research and development (1,555) - Income tax effect of non-GAAP adjustments (2,747) (2,929) Net income on a non-GAAP basis $ $ 23,712 23,955 Three Months Ended Diluted net income per share reconciliation March 29, 2014 March 30, 2013 Diluted net income per share on a GAAP basis $ $ 0.32 0.31 Share-based compensation expense: - Cost of product sales 0.01 0.01 - Selling, general and administrative 0.07 0.07 - Research and development 0.04 0.03 Amortization of purchased intangibles: - Cost of product sales 0.02 0.03 - Selling, general and administrative 0.01 0.01 - Research and development 0.00 0.00 Acquisition-related contingent consideration adjustments: - Selling, general and administrative 0.02 - Research and development (0.03) Income tax effect of non-GAAP adjustments (0.05) (0.05) Diluted net income per share on a non-GAAP $ $ basis 0.41 0.41 Three Months Ended March 29, 2014 March 30, 2013 Shares used to compute diluted net income per share reconciliation Shares used in calculation of diluted net income per share -- 57,666 58,507 GAAP and non-GAAP The following table reconciles the specific items excluded from GAAP gross profit and gross margin in the calculation of non-GAAP gross profit and gross margin for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Gross Profit (Unaudited) (in thousands) Three Months Ended March 29, 2014 March 30, 2013 Gross profit on a GAAP basis $ 68.2% $ 70.2% 85,671 82,652 Share-based compensation expense 621 571 Amortization of purchased 1,013 1,714 intangibles Gross profit on a non-GAAP basis $ 69.5% $ 72.1% 87,305 84,937 The following table reconciles the specific items excluded from GAAP operating expenses in the calculation of non-GAAP operating expenses for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Operating Expenses (Unaudited) (in thousands) Three Months Ended March 29, 2014 March 30, 2013 Operating expenses on a GAAP basis $ 58,840 $ 59,258 Share-based compensation expense: - Selling, general and administrative (4,025) (3,683) - Research and development (2,136) (1,913) Amortization of purchased intangibles: - Selling, general and administrative (760) (751) - Research and development (132) (82) Acquisition-related contingent consideration adjustments: - Selling, general and administrative (1,088) - - Research and development 1,555 - Operating expenses on a non-GAAP $ 52,254 $ 52,829 basis The following table reconciles the GAAP tax expense for the adjustments from GAAP net income to non-GAAP net income: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Tax Expense (Unaudited) (in thousands) Three Months Ended March 29, 2014 March 30, 2013 Tax expense on a GAAP basis $ 32.6% $ 25.9% 8,839 6,337 Share-based compensation expense 2,279 2,034 Amortization of purchased 648 895 intangibles Acquisition-related contingent (180) - consideration adjustments Tax expense on a non-GAAP basis $ 32.8% $ 27.9% 11,586 9,266 The following table reconciles guidance for gross margin and tax-effectednet income per diluted share on a GAAP and non-GAAP basis for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Forward-Looking Guidance (Unaudited) (in thousands, except for per share data) Gross margin For the Fiscal Year 2014 Gross margin on a GAAP basis 70.0% Amortization of purchased intangibles 0.7% Share-based compensation expense 0.3% Gross margin on a non-GAAP basis 71.0% Net income per diluted share reconciliation For the Fiscal Year 2014 From To Net income per diluted share on a GAAP basis $ 1.28 $ 1.38 Acquisition-related contingent consideration 0.01 0.01 adjustments Share-based compensation expense 0.33 0.33 Amortization of purchased intangibles 0.09 0.09 Tax rate effect on non-GAAP earnings 0.01 0.01 Net income per diluted share on a non-GAAP basis $ 1.72 $ 1.82 Shares used in calculation of net income per 57,800 57,800 diluted share - GAAP and Non-GAAP About Thoratec Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and markets the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com. Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and HeartMate III, HeartMate PHP, PVAD, IVAD and Pocket Controller are trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH. DuraHeart is a registered trademark of Terumo Corporation. Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2014 financial results or future performance contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "should," "hopes," "could," "will," "estimates," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products, including development and clinical trial timing, and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address quality issues adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. SOURCE Thoratec Corporation Website: http://www.thoratec.com Contact: Neil Meyer, Director of Investor Relations, Thoratec Corporation, (925) 738-0029
Thoratec® Reports First Quarter 2014 Results
Press spacebar to pause and continue. Press esc to stop.